Literature DB >> 10556833

CTL priming by CD8(+) and CD8(-) dendritic cells in vivo.

C Ruedl1, M F Bachmann.   

Abstract

Two distinct developmental pathways are driving the formation of myeloid- and lymphoid-related dendritic cells (DC) which differ in anatomical localization and phenotype. In terms of function, it has been hypothesized that only the myeloid-related CD8(-) DC are able to initiate immune responses, whereas the lymphoid-related CD8(+) DC have been suggested to induce tolerance. Here we show that both subsets activate CD8(+) T cells in vitro and induce protective anti-viral CTL responses in vivo. Thus, vaccine strategies using peptide-pulsed DC do not have to take into account DC subsets for priming.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10556833     DOI: 10.1002/(SICI)1521-4141(199911)29:11<3762::AID-IMMU3762>3.0.CO;2-F

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Induction of polyomavirus-specific CD8(+) T lymphocytes by distinct dendritic cell subpopulations.

Authors:  D R Drake; M L Shawver; A Hadley; E Butz; C Maliszewski; A E Lukacher
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Disparate ability of murine CD8alpha- and CD8alpha+ dendritic cell subsets to traverse endothelium is not determined by differential CD11b expression.

Authors:  Bridget L Colvin; Audrey H Lau; Amanda M Schell; Angus W Thomson
Journal:  Immunology       Date:  2004-11       Impact factor: 7.397

3.  Effective induction of acquired resistance to Listeria monocytogenes by immunizing mice with in vivo-infected dendritic cells.

Authors:  Hiroshi Sashinami; Akio Nakane; Yoichiro Iwakura; Mutsuo Sasaki
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

Review 4.  The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.

Authors:  Peter E Fecci; Duane A Mitchell; Gary E Archer; Michael A Morse; H Kim Lyerly; Darell D Bigner; John H Sampson
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

5.  CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.

Authors:  J M den Haan; S M Lehar; M J Bevan
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

6.  CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.

Authors:  Gabriel Morón; Paloma Rueda; Ignacio Casal; Claude Leclerc
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

7.  Functional comparison of mouse CIRE/mouse DC-SIGN and human DC-SIGN.

Authors:  Irina Caminschi; Alexandra J Corbett; Corina Zahra; Mireille Lahoud; Karen M Lucas; Mariam Sofi; David Vremec; Thomas Gramberg; Stefan Pöhlmann; Joan Curtis; Emanuela Handman; Serani L H van Dommelen; Peter Fleming; Mariapia A Degli-Esposti; Ken Shortman; Mark D Wright
Journal:  Int Immunol       Date:  2006-03-28       Impact factor: 4.823

8.  Lymphoid-related CD11c+ CD8alpha+ dendritic cells are involved in enhancing herpes simplex virus type 1 latency.

Authors:  Kevin R Mott; David Underhill; Steven L Wechsler; Homayon Ghiasi
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  Cell Type Preference of a Novel Human Derived Cell-Permeable Peptide dNP2 and TAT in Murine Splenic Immune Cells.

Authors:  Sangho Lim; Jung-Ah Lee; Ja-Hyun Koo; Tae Gun Kang; Sang-Jun Ha; Je-Min Choi
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.